PMID- 32431178
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20200917
IS  - 1793-6853 (Electronic)
IS  - 0192-415X (Linking)
VI  - 48
IP  - 4
DP  - 2020
TI  - Ginsenoside Rb2 Ameliorates LPS-Induced Inflammation and ER Stress in HUVECs and 
      THP-1 Cells via the AMPK-Mediated Pathway.
PG  - 967-985
LID - 10.1142/S0192415X20500469 [doi]
AB  - Inflammation and endoplasmic reticulum (ER) stress have been documented to 
      contribute to the development of atherosclerosis. Ginsenoside Rb2 has been 
      reported to exhibit antidiabetic effects. However, the effects of Rb2 on 
      atherosclerotic responses such as inflammation and ER stress in endothelial cells 
      and monocytes remain unclear. In this study, the expression of inflammation and 
      ER stress markers was determined using a Western blotting method. Concentrations 
      of tumor necrosis factor alpha (TNF[Formula: see text]) and monocyte 
      chemoattractant protein-1 (MCP-1) in culture media were assessed by enzyme-linked 
      immunosorbent assay (ELISA) and apoptosis was evaluated by a cell viability assay 
      and a caspase-3 activity measurement kit. We found that exposure of HUVECs and 
      THP-1 monocytes to Rb2 attenuated inflammation and ER stress, resulting in 
      amelioration of apoptosis and THP-1 cell adhesion to HUVECs under 
      lipopolysaccharide (LPS) condition. Increased AMPK phosphorylation and heme 
      oxygenase (HO)-1 expression, including GPR120 expression were observed in 
      Rb2-treated HUVECs and THP-1 monocytes. Downregulation of both, AMPK 
      phosphorylation and HO-1expression rescued these observed changes. Furthermore, 
      GPR120 siRNA mitigated Rb2-induced AMPK phosphorylation. These results suggest 
      that Rb2 inhibits LPS-mediated apoptosis and THP-1 cell adhesion to HUVECs by 
      GPR120/AMPK/HO-1-associated attenuating inflammation and ER stress. Therefore, 
      Rb2 can be used as a potential therapeutic molecule for treatment of 
      atherosclerosis.
FAU - Sun, Jaw Long
AU  - Sun JL
AD  - Department of Pharmacology, College of Medicine, Chung-Ang University, Seoul, 
      Republic of Korea.
FAU - Abd El-Aty, A M
AU  - Abd El-Aty AM
AD  - Department of Medical Pharmacology, Medical Faculty, Ataturk University, Erzurum, 
      Turkey.
AD  - Department of Pharmacology, Faculty of Veterinary Medicine, Cairo University, 
      12211 Giza, Egypt.
FAU - Jeong, Ji Hoon
AU  - Jeong JH
AD  - Department of Pharmacology, College of Medicine, Chung-Ang University, Seoul, 
      Republic of Korea.
FAU - Jung, Tae Woo
AU  - Jung TW
AD  - Department of Pharmacology, College of Medicine, Chung-Ang University, Seoul, 
      Republic of Korea.
LA  - eng
PT  - Journal Article
DEP - 20200520
PL  - Singapore
TA  - Am J Chin Med
JT  - The American journal of Chinese medicine
JID - 7901431
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (FFAR4 protein, human)
RN  - 0 (Ginsenosides)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Receptors, G-Protein-Coupled)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 11021-13-9 (ginsenoside Rb2)
RN  - EC 1.14.14.18 (HMOX1 protein, human)
RN  - EC 1.14.14.18 (Heme Oxygenase-1)
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
SB  - IM
MH  - AMP-Activated Protein Kinases/*metabolism
MH  - Apoptosis/drug effects/genetics
MH  - Atherosclerosis/chemically induced/*drug therapy/genetics
MH  - Chemokine CCL2/genetics/metabolism
MH  - Endoplasmic Reticulum Stress/*drug effects/*genetics
MH  - Gene Expression/drug effects
MH  - Ginsenosides/*pharmacology/*therapeutic use
MH  - Heme Oxygenase-1/genetics/metabolism
MH  - Human Umbilical Vein Endothelial Cells
MH  - Humans
MH  - Inflammation
MH  - Lipopolysaccharides/*adverse effects
MH  - Phosphorylation/drug effects
MH  - *Phytotherapy
MH  - Receptors, G-Protein-Coupled/genetics/metabolism
MH  - Signal Transduction/*drug effects/*genetics
MH  - THP-1 Cells
MH  - Tumor Necrosis Factor-alpha/genetics/metabolism
OTO - NOTNLM
OT  - AMPK
OT  - Apoptosis
OT  - Atherosclerosis
OT  - Ginsenoside
OT  - HO-1
OT  - Inflammation
OT  - Rb2
EDAT- 2020/05/21 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
PHST- 2020/05/21 06:00 [entrez]
AID - 10.1142/S0192415X20500469 [doi]
PST - ppublish
SO  - Am J Chin Med. 2020;48(4):967-985. doi: 10.1142/S0192415X20500469. Epub 2020 May 
      20.